EP3246029A1 — Pharmaceutical combination of nintedanib and capecitabine for the treatment of colorectal cancer
Assigned to Boehringer Ingelheim International GmbH · Expires 2017-11-22 · 8y expired
What this patent protects
The compounds • 3-Z-[1-(4-( N -((4-methyl-piperazin-1-yl)-methylcarbonyl)- N -methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and • 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine or a pharmaceutically …
USPTO Abstract
The compounds • 3-Z-[1-(4-( N -((4-methyl-piperazin-1-yl)-methylcarbonyl)- N -methyl-amino)-anilino)-1-phenyl-methylene]-6-methoxycarbonyl-2-indolinone or a pharmaceutically acceptable salt thereof, and • 5'-deoxy-5-fluoro-N-[(pentyloxy)carbonyl]-cytidine or a pharmaceutically acceptable salt thereof, for combined use in the treatment of colorectal cancer.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.